Black Diamond Therapeutics (BDTX) Short-term Investments (2020 - 2026)

Black Diamond Therapeutics (BDTX) has 7 years of Short-term Investments data on file, last reported at $88.2 million in Q1 2026.

• Quarterly Short-term Investments rose 63.38% year-over-year to $88.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.2 million (up 63.38% YoY) and the FY2025 annual result came in at $107.7 million, up 73.26% from the prior year.
• Short-term Investments retreated to $88.2 million in Q1 2026, from $107.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $125.7 million in Q1 2022 to a low of $47.6 million in Q2 2023.
• A 5-year average of $87.1 million and a median of $89.3 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2023 — Short-term Investments tumbled 54.64% — and 2024, when it soared 89.26%.
• Tracing BDTX's Short-term Investments over 5 years: stood at $88.5 million in 2022, then fell by 15.04% to $75.2 million in 2023, then dropped by 17.35% to $62.1 million in 2024, then soared by 73.26% to $107.7 million in 2025, then slipped by 18.09% to $88.2 million in 2026.
• The last three Short-term Investments figures came in at $88.2 million (Q1 2026), $107.7 million (Q4 2025), and $104.6 million (Q3 2025), per Business Quant data.